Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API

Parkinson's Disease Mechanisms and Treatments

146 ta ish

  1. Oxidation-induced destabilization of polymorphic α-synuclein fibrils: insights from molecular dynamics

    Tohir Vohidovich Akramov, Parthiban Marimuthu, Mukhriddin Makhkamov +3

    MaqolaParkinson's Disease Mechanisms and TreatmentsFrontiers in Physics20250 iqtibos
    ABI

  2. Combined Neurometabolic Therapy in Various Clinical Forms of Tic Hyperkinesis in Children: Effects on Motor and Non-Motor Symptoms

    Dilorom A. Nurmatova, Z. F. Sayfitdinkhuzhaev, Н. Г. Жукова +3

    MaqolaObsessive-Compulsive Spectrum DisordersPersonalized Psychiatry and Neurology20250 iqtibos
    ABI

  3. Treatment of Parkinson’s Disease with an Anti-Inflammasome NLRP3 Inhibitor Derived from a Natural Product

    Wenqian Li, Jiu‐liang Zhang, Qiang Chen +13

    MaqolaInflammasome and immune disordersACS Pharmacology & Translational Science20250 iqtibos
    ABI

  4. THE INFLUENCE OF MOTOR FLUCTUATIONS ON PSYCHOEMOTIONAL STATUS AND QUALITY OF LIFE IN PARKINSON'S DISEASE

    O. Naimov, Rustambek Matmurodov, B. Muminov

    MaqolaParkinson's Disease Mechanisms and TreatmentsMedical science of Uzbekistan20250 iqtibos
    ABI

  5. «Brain—gut—microbiome» axis in patients with Parkinson’s disease

    Н. Г. Жукова, Z. F. Sayfitdinkhuzhaev, G.M. Israilova +5

    MaqolaParkinson's Disease Mechanisms and TreatmentsS S Korsakov Journal of Neurology and Psychiatry20250 iqtibos
    ABI

  6. Serum ferritin levels in the exacerbation of motor symptoms in Parkinson's disease

    B. Muminov, Rustambek Matmurodov, O. Naimov +1

    MaqolaParkinson's Disease Mechanisms and TreatmentsJournal of the Neurological Sciences20250 iqtibos
    ABI

  7. MCP-1: The role of a novel biomarker in assessing neuroinflammation in Parkinson’s disease and Parkinson-plus syndromes

    D. Akramova, G. Rakhimbaeva, Turdikul Bobomuratov +2

    MaqolaNeuroinflammation and Neurodegeneration MechanismsJournal of the Neurological Sciences20250 iqtibos
    ABI

  8. Biomarkers at the crossroads of inflammation and degeneration in Parkinson’s disease: The diagnostic potential of MCP-1 and alpha-synuclein

    D. Akramova, G. Rakhimbaeva, T. Bobomuratov +1

    MaqolaParkinson's Disease Mechanisms and TreatmentsJournal of the Neurological Sciences20250 iqtibos
    ABI

  9. Type 2 diabetes as a modifier of motor and non-motor symptoms and biomarkers in Parkinson's disease: A comparative study in the population of Uzbekistan

    Dilyora Pulatova, F.S. Saidvaliyev, Bekhzod Pulatov +1

    MaqolaParkinson's Disease Mechanisms and TreatmentsJournal of the Neurological Sciences20250 iqtibos
    ABI

  10. Association between serum Mcp-1 levels and motor impairment severity in Parkinson’s disease and Parkinson-plus syndromes

    D. Akramova, G. Rakhimbaeva, Turdikul Bobomuratov +2

    MaqolaParkinson's Disease Mechanisms and TreatmentsJournal of the Neurological Sciences20250 iqtibos
    ABI

  11. Assisted Living Applications Addressing Sleep Dysfunction in Parkinson's Patients

    Nozima Zufarova, Shakhzoda Aripkhodjaeva, Dilorom Zakirova +3

    MaqolaSleep and related disorders20250 iqtibos
    ABI

  12. SURXONDARYO VILOYATIDA PARKINSON KASALLIGINING TARQALISH CHASTOTASI VA KASALLIK ASORATLARI

    Choriyev Shohjahon Habibullo o'g'li, Alimova Zebiniso Farxodjon qizi

    MaqolaNeurological Disorders and TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  13. SURXONDARYO VILOYATIDA PARKINSON KASALLIGINING TARQALISH CHASTOTASI VA KASALLIK ASORATLARI

    Choriyev Shohjahon Habibullo o'g'li, Alimova Zebiniso Farxodjon qizi

    MaqolaNeurological Disorders and TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  14. The Brain–Gut–Microbiome Axis in Patients with Parkinson’s Disease

    N. G. Zhukova, Z. F. Sayfitdinkhuzhaev, G. M. Israilova +5

    MaqolaParkinson's Disease Mechanisms and TreatmentsNeuroscience and Behavioral Physiology20260 iqtibos
    ABI

  15. Rotenone-Induced Dysregulation of Synaptosomal Ca²⁺ And Hypokinetic Behavior in A Rat Model of Parkinsonism

    Zayniyeva Makhbuba, Izzatillaeva Sabina, Tajiyeva Oyimjan +4

    MaqolaMitochondrial Function and PathologyThe American Journal of Applied Sciences20260 iqtibos
    ABI

  16. EARLY DIAGNOSIS OF SECONDARY LEGS SYNDROME, TAKING INTO ACCOUNT CLINICAL AND NEUROPHYSIOLOGICAL PARAMETERS

    Заррина Обидовна Исмати, Aziza Taxirovna Djurabekova

    MaqolaRestless Legs Syndrome ResearchZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  17. EARLY DIAGNOSIS OF SECONDARY LEGS SYNDROME, TAKING INTO ACCOUNT CLINICAL AND NEUROPHYSIOLOGICAL PARAMETERS

    Заррина Обидовна Исмати, Aziza Taxirovna Djurabekova

    MaqolaRestless Legs Syndrome ResearchZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  18. ABSTRACT NUMBER: ESOC2026A1995 FEATURES OF NON-MOTOR DISORDERS IN VASCULAR PARKINSONISM

    Shodlik Jumaniyozov, R J Matmurodov, R. Juraev +2

    MaqolaNeurological Disorders and TreatmentsEuropean Stroke Journal20260 iqtibos
    ABI

  19. Serum ferritin, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio are associated with levodopa-induced dyskinesia severity in Parkinson’s disease

    F.S. Saidvaliyev, Dilyora Pulatova, I.A. Kilichev +8

    MaqolaParkinson's Disease Mechanisms and TreatmentsBMC Neurology20260 iqtibos
    ABI

  20. 485 Mortality trends in patients with co-occurring heart failure and parkinson’s disease in the United States: a multiple cause of death analysis, 1999-2020

    Suleman Saeed, Hamid Bin Tariq, Bisma Tariq +13

    MaqolaHeart Failure Treatment and Management20260 iqtibos
    ABI

  21. Peripheral Iron and Immune Markers Are Associated With Levodopa-Induced Dyskinesia Severity in Parkinson’s Disease

    F.S. Saidvaliyev, Dilyora Pulatova, I.A. Kilichev +8

    PreprintParkinson's Disease Mechanisms and TreatmentsResearch Square20260 iqtibos
    ABI